Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Int J Hematol ; 115(2): 278-286, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34709580

ABSTRACT

OBJECTIVE: The cost-effectiveness of NUDT15 genetic testing-guided initial 6-mercaptopurine (6-MP) dosing in children with acute lymphoblastic leukemia (ALL) was evaluated. METHODS: A decision tree model was used to evaluate the cost to China's medical system per quality-adjusted life-year (QALY) gained and cost per case of severe leukopenia avoided of NUDT15 genetic testing using public clinical data. RESULTS: Genetic testing-guided initial 6-MP dosing reduced overall costs by $518.61, and prevented 0.221 cases of Grade III-IV leukopenia and increased QALY by 0.00136 per patient. Results were robust in one-way analyses and probabilistic sensitivity analyses. CONCLUSION: NUDT15 genetic testing prior to the initial administration of 6-MP in pediatric ALL patients in China is less expensive than standard dosing without genetic testing.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Genetic Testing/economics , Mercaptopurine/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Pyrophosphatases/genetics , Antimetabolites, Antineoplastic/economics , Child , China , Cost-Benefit Analysis , Humans , Mercaptopurine/economics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/economics , Quality-Adjusted Life Years
2.
J Crohns Colitis ; 13(7): 838-845, 2019 Jul 25.
Article in English | MEDLINE | ID: mdl-30698675

ABSTRACT

BACKGROUND AND AIMS: Decreased thiopurine S-methyltransferase [TPMT] enzyme activity increases the risk of haematological adverse drug reactions [ADRs] in patients treated with thiopurines. Clinical studies have shown that in patients with inflammatory bowel disease [IBD], pharmacogenetic TPMT-guided thiopurine treatment reduces this risk of ADRs. The aim of this study was to investigate whether this intervention impacts on healthcare costs and/or quality of life. METHODS: An a priori defined cost-effectiveness analysis was conducted in the Thiopurine response Optimization by Pharmacogenetic testing in Inflammatory bowel disease Clinics [TOPIC] trial, a randomized controlled trial performed in 30 Dutch hospitals. Patients diagnosed with IBD [age ≥18 years] were randomly assigned to the intervention [i.e. pre-treatment genotyping] or control group. Total costs in terms of volumes of care, and effects in quality-adjusted life years [QALYs], based on EuroQol-5D3L utility scores, were measured for 20 weeks. Mean incremental cost savings and QALYs with confidence intervals were calculated using non-parametric bootstrapping with 1000 replications. RESULTS: The intervention group consisted of 381 patients and the control group 347 patients. The mean incremental cost savings were €52 per patient [95% percentiles -682, 569]. Mean incremental QALYs were 0.001 [95% percentiles -0.009, 0.010]. Sensitivity analysis showed that the results were robust for potential change in costs of screening, costs of biologicals and costs associated with productivity loss. CONCLUSIONS: Genotype-guided thiopurine treatment in IBD patients reduced the risk of ADRs among patients carrying a TPMT variant, without increasing overall healthcare costs and resulting in comparable quality of life, as compared to standard treatment.


Subject(s)
Azathioprine/administration & dosage , Azathioprine/economics , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/economics , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/genetics , Mercaptopurine/administration & dosage , Mercaptopurine/economics , Adult , Age of Onset , Cost-Benefit Analysis , Female , Genotype , Humans , Male , Methyltransferases , Netherlands , Quality of Life
3.
J Pediatr Psychol ; 43(7): 758-768, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29771338

ABSTRACT

Objective: Improving medication adherence among children with B-cell precursor acute lymphoblastic leukemia (B-ALL) has the potential to reduce relapse rates but requires an investment in resources. An economic evaluation is needed to understand the potential costs and benefits of delivering adherence-promotion interventions (APIs) as part of standard clinical care. Methods: A Markov decision analytic model was used to simulate the potential incremental cost-effectiveness per quality-adjusted life year (QALY) to be gained from an API for children with B-ALL in first continuous remission compared with treatment as usual (TAU, no intervention). Model parameter estimates were informed by previously published studies. The primary outcome was incremental cost (2015 US$) per QALY gained for API compared with TAU. Results: The model predicts the API to result in superior health outcomes (4.87 vs. 4.86 QALYs) and cost savings ($43,540.73 vs. $46,675.71) as compared with TAU, and simulations indicate that, across a range of plausible parameter estimates, there is a 95% chance that the API is more effective and less costly than TAU. The API was estimated to remain more effective and less costly than TAU in situations where the prevalence of nonadherence exceeds 32% and when API improves baseline adherence in at least 3% of patients. Conclusions: Providing APIs to children with B-ALL may improve health outcomes and save costs over a 6-year period.


Subject(s)
Antimetabolites, Antineoplastic/economics , Antimetabolites, Antineoplastic/therapeutic use , Cost-Benefit Analysis/methods , Leukemia/drug therapy , Markov Chains , Medication Adherence/statistics & numerical data , Adolescent , Adult , Child , Child, Preschool , Cost Savings , Cost-Benefit Analysis/economics , Cost-Benefit Analysis/statistics & numerical data , Humans , Infant , Mercaptopurine/economics , Mercaptopurine/therapeutic use , Quality-Adjusted Life Years , Young Adult
4.
Scand J Gastroenterol ; 51(6): 753-62, 2016.
Article in English | MEDLINE | ID: mdl-26762679

ABSTRACT

OBJECTIVE: Therapy for autoimmune hepatitis has been prednisone based for decades; however, budesonide may be equally effective with fewer side effects. Our aim was to evaluate quality-adjusted life years and health care costs of three different treatment regimens. MATERIALS AND METHODS: Treatment using prednisone, budesonide or a combination of both over a three-year period in newly diagnosed children with type I autoimmune hepatitis were simulated with a Markov model. Transition probabilities were calculated over consecutive three-month period. Costs were determined from a hospital database and health utilities were estimated from the literature. A Monte Carlo probabilistic sensitivity analysis was used to simulate the outcomes of 5000 patients in each treatment arm. RESULTS: Compared to standard therapy, budesonide leads to a gain of 0.09 quality-adjusted life years, costing $17,722 per QALY over a three-year period. Standard therapy led to significantly lower QALY's compared to other strategies (p < 0.001). Health utilities of patients in remission in each treatment group had the greatest impact on the model. Budesonide remained the treatment of choice if the probability of inducing remission was 55% or greater. CONCLUSIONS: Budesonide therapy in non-cirrhotic, treatment naïve patients with type I autoimmune hepatitis yielded greater QALY's compared to the current standard therapy with an acceptable increase in costs.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Budesonide/therapeutic use , Health Care Costs/statistics & numerical data , Hepatitis, Autoimmune/drug therapy , Quality-Adjusted Life Years , Adolescent , Anti-Inflammatory Agents/economics , Budesonide/economics , Child , Child, Preschool , Decision Support Techniques , Drug Administration Schedule , Drug Therapy, Combination , Follow-Up Studies , Hepatitis, Autoimmune/economics , Humans , Illinois , Markov Chains , Mercaptopurine/analogs & derivatives , Mercaptopurine/economics , Mercaptopurine/therapeutic use , Monte Carlo Method , Prednisone/economics , Prednisone/therapeutic use , Treatment Outcome
5.
Inflamm Bowel Dis ; 18(9): 1608-16, 2012 Sep.
Article in English | MEDLINE | ID: mdl-21905173

ABSTRACT

BACKGROUND: A number of treatments have been shown to reduce the risk of postoperative recurrence of Crohn's disease (CD). The optimal strategy is unknown. The aim was to evaluate the comparative cost-effectiveness of postoperative strategies to prevent clinical recurrence of CD. METHODS: Three prophylactic strategies were compared to "no prophylaxis"; mesalamine, azathioprine (AZA) / 6-mercaptopurine (6-MP), and infliximab. The probability of clinical recurrence, endoscopic recurrence, and therapy discontinuation due to adverse drug reactions (ADRs) were extracted from randomized controlled trials (RCTs). Quality-of-life scores and treatment costs were derived from published data. The primary model evaluated quality-adjusted life years (QALYs) and cost-effectiveness at 1 year after surgery. Sensitivity analysis assessed the impact of a range of recurrence rates on cost-effectiveness. An exploratory analysis evaluated cost-effectiveness outcomes 5 years after surgery. RESULTS: A strategy of "no prophylaxis" was the least expensive one at 1 and 5 years after surgery. Compared to this approach, AZA/6-MP had the most favorable incremental cost-effectiveness ratio (ICER) ($299,188/QALY gained), and yielded the highest net health benefits of the medication strategies at 1 year. Sensitivity analysis determined that the ICER of AZA/6-MP was preferable to mesalamine up to a recurrence rate of 52%, but mesalamine dominated at higher rates. In the 5-year exploratory analysis, mesalamine had the most favorable ICER over 5 years ($244,177/QALY gained). CONCLUSIONS: Compared to no prophylactic treatment, AZA/6-MP has the most favorable ICER in the prevention of clinical recurrence of postoperative CD up to 1 year. At 5 years, mesalamine had the most favorable ICER in this model.


Subject(s)
Antibodies, Monoclonal/economics , Azathioprine/economics , Crohn Disease/drug therapy , Crohn Disease/economics , Mercaptopurine/economics , Mesalamine/economics , Secondary Prevention , Anti-Inflammatory Agents, Non-Steroidal/economics , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Azathioprine/therapeutic use , Cost-Benefit Analysis , Crohn Disease/surgery , Decision Trees , Health Care Costs , Humans , Immunosuppressive Agents/economics , Immunosuppressive Agents/therapeutic use , Infliximab , Mercaptopurine/therapeutic use , Mesalamine/therapeutic use , Monte Carlo Method , Postoperative Period , Quality-Adjusted Life Years , Randomized Controlled Trials as Topic
7.
Inflamm Bowel Dis ; 14(1): 53-60, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17973301

ABSTRACT

BACKGROUND: Studies examining the treatment reality of IBD patients in Germany have been limited, as networking among deliverers of care and reliable documentation of medical, demographic, and economic data are lacking. The aim of the present study was to establish an internet-based treatment registry in order to evaluate treatment of IBD patients in Germany. METHODS: Between November 1(st), 2005, and January 31, 2007, 1024 outpatients with prevalent IBD from 10 gastroenterological private practices and 3 hospitals (UC = 439, CD = 567, ID = 18) were enrolled in the study. An internet-based registry was established that included data about medical history, disease status, diagnostic procedures, laboratory test results, and medical treatment. Data for private practices and hospitals were pooled in order to compare treatment habits between these types of medical facilities. The cost of medication was determined according to medications prescribed. RESULTS: There was no significant difference between the 2 patient groups in demographic and clinical characteristics. Marked differences were observed in medical treatment. The most frequently prescribed medications in the private practices for patients in remission and those with active disease were aminosalicylates and corticosteroids. Immunomodulators played a marginal role. In contrast, in the hospitals azathioprine/6-MP was predominantly used for the maintenance of remission. Patients with fistulizing CD were treated with infliximab. The mean annual cost of medications was 1826 +/- 1331euro/patient (median 1353euro) in the private practices and 1849euro +/- 2897euro/patient (median 960euro) at the University Hospital. CONCLUSIONS: The registry provides the first detailed data about the reality of treatment of IBD patients in Germany and reveals the necessity for networking among attending physicians in order to implement guidelines-conformed treatment.


Subject(s)
Anti-Inflammatory Agents/economics , Anti-Inflammatory Agents/therapeutic use , Immunosuppressive Agents/economics , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/economics , Adrenal Cortex Hormones/economics , Adrenal Cortex Hormones/therapeutic use , Adult , Aminosalicylic Acids/economics , Aminosalicylic Acids/therapeutic use , Antibodies, Monoclonal/economics , Antibodies, Monoclonal/therapeutic use , Azathioprine/economics , Azathioprine/therapeutic use , Cost of Illness , Female , Germany , Humans , Infliximab , Inpatients , Internet , Male , Mercaptopurine/economics , Mercaptopurine/therapeutic use , Middle Aged , Outpatients , Prospective Studies , Registries
8.
Ter Arkh ; 79(7): 19-26, 2007.
Article in Russian | MEDLINE | ID: mdl-17802785

ABSTRACT

AIM: A comparative analysis of efficacy and toxicity of two chemotherapy regimens: standard German protocol ALL-BFM 90m and less intensive original test protocol ALL-MB 91 in a multicenter trial of acute lymphoblastic leukemia (ALL) in children. MATERIAL AND METHODS: In 1995-2002 a total of 834 patients with newly diagnosed ALL aged 0-18 years were admitted to 10 clinics of Russia. Of them, 713 were randomized in two groups: treatment program ALL-BFM 90m (n = 355) and ALL-MB 91 program (n = 358). RESULTS: In 7-year follow-up median, 10-year event-free survival (EFS) and overall survival (OS) did not differ significantly between the groups and was 67 +/- 3 and 68 +/- 3% (ALL-MB 91) and 74 +/- 2, 71 +/- 3% (ALL-BFM 90m), respectively. Though the rate of isolated recurrences in CNS in patients on the protocol ALL-MB 91 was 2.8%, they developed only in 0.8% patients of the standard risk group. Anemia, thrombocytopenia and agranulocytosis developed less frequently, hospital stay was significantly shorter on the test protocol vs the control one (p < 0.01). CONCLUSION: EFS and OS on the test (ALL-MB 91) and control (ALL-BFM 90m) protocols were equivalent in lower toxicity and cost of therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asparaginase/adverse effects , Asparaginase/economics , Asparaginase/therapeutic use , Child , Child, Preschool , Cyclophosphamide/adverse effects , Cyclophosphamide/economics , Cyclophosphamide/therapeutic use , Cytarabine/adverse effects , Cytarabine/economics , Cytarabine/therapeutic use , Daunorubicin/adverse effects , Daunorubicin/economics , Daunorubicin/therapeutic use , Female , Humans , Male , Mercaptopurine/adverse effects , Mercaptopurine/economics , Mercaptopurine/therapeutic use , Methotrexate/adverse effects , Methotrexate/economics , Methotrexate/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Prednisone/adverse effects , Prednisone/economics , Prednisone/therapeutic use , Treatment Outcome , Vincristine/adverse effects , Vincristine/economics , Vincristine/therapeutic use
9.
Am J Gastroenterol ; 100(10): 2239-47, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16181376

ABSTRACT

BACKGROUND: Azathioprine (AZA) is effective for the maintenance of a steroid free remission in Crohn's disease (CD). Thiopurine methyltransferase (TPMT) is important for the metabolism of AZA and influences the production of active AZA metabolites. AZA dose selection based on pharmacogenetic testing of TPMT and metabolite monitoring (MM) may offer a safety and efficacy advantage over traditional dosing strategies. We performed a decision analysis to estimate the potential costs and effectiveness of TPMT screening and MM as disease management strategies for CD. METHODS: Strategies applying TPMT and/or MM to influence treatment decisions were compared to community care (CC). The impact on toxicity minimization and improved time to initial and sustained response was evaluated. A 1-yr model was developed from the third-party payer perspective for mild to moderately chronically active, steroid-treated CD patients. Effectiveness and toxicity defined by time to response CD activity index (CDAI <150, +/- steroids) or time to sustained response (CDAI <150, off steroids x 8 wk) and reduction in leukopenic events, respectively. One- and two-way sensitivity analyses were conducted to determine the effect of varying individual estimates from those used in the base-case analysis. RESULTS: MM, TPMT, and TPMT + MM strategies as compared to CC achieved an earlier time to initial response (18.66, 18.96, and 19.10 vs. 22.41 wk, respectively) and sustained response (39.83, 42.91, and 39.8 vs. 45.36 wk, respectively). The least costly strategy at 1 yr was TPMT ($3,861) and the most costly strategy was CC ($7,142). Each alternative strategy was shown to dominate CC (i.e., less costs and faster time to response or sustained response). The cost-effectiveness rankings were robust to sensitivity analyses on key variables. CONCLUSION: The addition of alternative strategies to CC may improve AZA outcomes and reduce the total cost of care for steroid treated chronically active CD patients, with TPMT being more beneficial for initial response to treatment and MM being more beneficial for sustained response to treatment.


Subject(s)
Community Health Services/economics , Crohn Disease/genetics , Crohn Disease/metabolism , Drug Monitoring/economics , Genetic Testing/economics , Health Care Costs , Azathioprine/administration & dosage , Azathioprine/blood , Azathioprine/economics , Cost-Benefit Analysis , Crohn Disease/drug therapy , Dose-Response Relationship, Drug , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Immunosuppressive Agents/economics , Mercaptopurine/administration & dosage , Mercaptopurine/blood , Mercaptopurine/economics , Methyltransferases/genetics , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...